GleamWall
中文EN

COGT Cogent Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1622229 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-38.5%
TTM EPS YoY-10.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-99.6%
ROA-64.8%
ROIC (approx.)-89.9%
Asset turnover—

Leverage & solvency

Liabilities / assets38.0%
Debt / equity0.43x
Current ratio10.99x
Interest coverage-85.23x

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-13.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$75.10M$70.81M$75.36M$75.56M$68.99M$62.20M$63.03M$62.05M
SG&A expense$42.09M$31.83M$28.24M$23.93M$14.37M$13.38M$11.90M$11.69M
Operating income-$117.18M-$102.64M-$103.61M-$99.49M-$83.36M-$75.58M-$74.93M-$73.73M
Interest expense$1.24M$1.22M$1.21M$1.29M$1.46M$314,000——
Net income-$111.43M-$96.41M-$97.35M-$102.49M-$80.93M-$73.53M-$71.99M-$67.93M
EBITDA-$116.61M-$101.90M-$102.98M-$98.83M-$82.71M-$74.93M-$74.29M-$73.06M
EPS (basic)-0.59-0.52-0.53—-0.50-0.53-0.52—
EPS (diluted)-0.59-0.52-0.53—-0.50-0.53-0.52—
Weighted avg. shares (diluted)173.13M171.01M162.19M—137.55M114.47M113.31M—
Balance sheet
Cash & equivalents$217.46M$181.17M$241.21M$312.01M$125.63M$127.60M$126.00M$98.17M
Short-term investments$573.67M$611.13M$625.17M$588.75M$265.59M$110.25M$119.66M$188.91M
Current assets$803.58M$804.82M$877.80M$910.36M$397.24M$245.01M$252.88M$296.47M
PP&E, net$4.31M$4.78M$5.30M$5.46M$5.27M$5.85M$6.45M$6.47M
Total assets$832.14M$834.55M$903.01M$937.61M$425.93M$274.82M$283.80M$327.90M
Current liabilities$73.12M$59.30M$57.98M$63.95M$62.25M$58.42M$49.32M$55.71M
Long-term debt$223.74M$223.46M$223.17M$222.90M$44.25M$43.95M—$0
Total debt$223.74M$223.46M$223.17M$222.90M$44.25M$43.95M—$0
Total liabilities$315.88M$302.16M$295.31M$301.24M$123.47M$119.78M$64.80M$71.61M
Shareholders' equity$516.26M$532.39M$607.69M$636.37M$302.46M$155.04M$219.00M$256.29M
Net debt$6.28M$42.28M-$18.04M-$89.12M-$81.38M-$83.65M—-$98.17M
Shares outstanding173.98M171.60M170.77M160.98M139.83M113.93M113.86M110.46M
Cash flow statement
Operating cash flow-$80.79M-$77.27M-$86.88M-$79.11M-$64.29M-$54.54M-$66.51M-$60.58M
Capital expenditure$108,000$370,000$449,000$811,000$65,000$131,000$547,000$75,000
Free cash flow-$80.89M-$77.64M-$87.33M-$79.92M-$64.35M-$54.67M-$67.06M-$60.65M
Investing cash flow$37.31M$14.28M-$36.46M-$322.77M-$155.05M$8.91M$69.38M$61.67M
Financing cash flow$79.76M$2.96M$52.54M$588.67M$217.37M$47.23M$24.97M$26,000
Depreciation & amortization$572,000$741,000$626,000$664,000$641,000$655,000$640,000$675,000
Stock-based compensation$16.87M$17.11M$16.91M$15.75M$10.60M$9.72M$10.01M$9.98M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.